Three more health apps obtained reimbursement in Germany

24

May 2023

Between late April and May 2023, three more health apps were introduced in the Directory of digital health applications (DiGAs) at the Federal Office for Drugs and Medical Devices (BfArM) and thus became reimbursable. These apps can be prescribed by physicians and psychotherapists and will be reimbursed by health insurers. In total, 47 health apps are currently available in the DiGA Directory, and six health apps were delisted from the Directory.

On April 21, 2023, "Selfapys Online-Kurs bei chronischen Schmerzen", developed by Selfapy GmbH, Germany, was introduced in the Directory. It is a digital application for patients suffering from chronic pain. The course imparts methods and techniques based on cognitive behavioral therapy and supports implementing and documenting the exercises intended to improve the user's symptoms. The online course for chronic pain can be used in the sense of multimodal pain therapy to accompany an existing treatment, to bridge the waiting time for therapy, and for stand-alone therapy with the digital health app. The app is available in German with a tariff of €540.

"NeuroNation MED", developed by Synaptikon GmbH, Germany, was introduced in the Directory on May 13, 2023. It is a mobile application for personalized cognitive training based on exercises of various cognitive functions (Multi-Domain Cognitive Training). "NeuroNation MED" aims to support patients in alleviating the symptoms of mild acquired or neurodegenerative cognitive impairment. The app offers two core elements: personalized cognitive training and health information. Cognitive training is adapted to the personal abilities and needs of the patients based on their performance in training and recurring evaluations. The health information provides data on brain health and animated instructions for mental and physical relaxation exercises. The effectiveness of the training plan is continuously optimized through interactions with the user. The app is available in German and English with a tariff of €499.

On May 15, 2023, "ProHerz", developed by ProCarement GmbH, Germany, was introduced in the Directory. "ProHerz" is a therapy companion for patients with heart failure to support self-management and as an early warning system to identify changes in the course of the disease. For this purpose, the vital signs measured daily by the patients (blood pressure, oxygen saturation, pulse, temperature, weight) are recorded in mobile devices (smartphone, tablet) and analyzed automatically. This makes it possible to document and monitor the state of health of patients independently. In addition, based on this data and the individual health and therapy profile, "ProHerz" offers digitally implemented and personalized health coaching and other risk prevention functions. The app is available in German with a range of tariffs of €495-€605.

The full details in German can be found here (Selfapys Online-Kurs bei chronischen Schmerzen), here (NeuroNation MED), and here (ProHerz).

This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news).

Not ready for a subscription service? Subscribe to our free-of-charge newsletter delivered every second week to get updates about key reimbursement developments in Europe (10-12 news every two weeks). First EU issues of both newsletters are available for download free-of-charge.

The latest related news

08

Jun 2023

In the period of April-May 2023, the Galician Agency for Health Technology Assessment (AVALIA-T) initiated the five health technology assessments referred to IVD, nephrology and urology, obstetrics and gynecology, pulmonary and airways as well as surgical procedures technology groups. The assessments on stereotactic virtual navigation system for percutaneous puncture as well as tumor ablation and invasive telemonitoring of pulmonary pressure in patients with heart failure were released.

Read more

07

Jun 2023

In May 2023, the National Institute for Health and Care Excellence (NICE) published one new Interventional Procedure Guidance (intramuscular diaphragm stimulation for ventilator-dependent chronic respiratory failure from high spinal cord injuries), two new Diagnostic Guidance (MRI fusion biopsy systems for diagnosing prostate cancer, automated ankle-brachial pressure index measurement devices to detect peripheral arterial disease), and three new Health Technology Evaluations (Digitally enabled therapies for adults with anxiety disorders / with depression, and point-of-care tests for urinary tract infections). Also, four clinical guidelines were updated.

Read more

06

Jun 2023

The French National Authority for Health (HAS) released new recommendations about add-on reimbursement of medical devices and medical aids from the meetings of the National Commission for Evaluation of Medical Devices and Health Technologies (CNEDiMTS) in May 2023. Twenty-one recommendations were published in relation to the registration, modification of registration conditions, and renewal of registration for devices in the List of reimbursable products and services (LPPR). Opinions concern cardiovascular and peripheral vascular, endocrine, ENT, gastrointestinal, and orthopedic devices, as well as medical aids.

Read more

02

Jun 2023

On May 15, 2023, the Innovation Committee at the Federal Joint Committee (G-BA) published the decisions, recommending the transfer to standard care for another three completed projects. The projects relate to controlling drug prescriptions in outpatient settings, evaluating the effectiveness of outpatient extensive stuttering therapy in primary school children, and the efficacy of cross-sectoral care models in psychiatry.

Read more

01

Jun 2023

On May 23, 2023, the Ministry of Health and Prevention published an Order in the Official Journal of the French Republic setting the tariffs for the medical telemonitoring activities covered by social health insurance in the context of the new framework. The tariffs will differ whether they bring an organizational or clinical (improvement in quality of life, morbidity, or mortality) benefit.

Read more